Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label JZP-110 safety study in narcolepsy or obstructive sleep apnea
NL-OMON45139Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of solriamfetol in narcolepsy and obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Treatment-emergent adverse events, Clinical laboratory tests and 10 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
solriamfetol
03
Conditions
narcolepsyobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on NL-OMON45139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45139.